Aptose Doses First CLL Patient in Phase 1 Study of CG-806 and Doses Third Cohort in Phase 1 Study of APTO-253

Ads

You May Also Like

Shire Acquires sanaplasma AG Boosting Plasma Collection Network for Immunology Franchise

Shire Acquires sanaplasma AG Boosting Plasma Collection Network for Immunology Franchise The acquisition of ...